Perspectives
Inside the Making of Reliable Medical Devices
Medical device reliability starts long before clinical use. Take a closer look at the quality controls behind the tools health...
Read more
Testosterone, HGH, and the Industrial Logic of Male Optimization
Testosterone replacement therapy has been practiced in some form since the 1940s, and the clinical indications for it — classical...
Read more
The Payer’s Dilemma: Choosing Between Negotiation Intelligence and Market Disclosure
The request-for-proposal processes that large health plans run for analytics vendors share a recurring structural problem: they ask MedPricer and...
Read more
The Thyroid Question
Levothyroxine has been among the top three most-prescribed medications in the United States for over a decade, with annual prescription...
Read more
The Long Shadow of the WHI
On July 9, 2002, the principal investigators of the estrogen-progestin arm of the Women's Health Initiative announced that they were...
Read more
The Audit That Changes Everything
Most organizations that consume drug pricing data never question it. The numbers arrive from CMS, from pricing compendia, from analytics...
Read more
The List Price Is a Lie Everyone Agrees to Tell
Every branded drug in America has a price that virtually no one pays. It is published, cited in earnings calls,...
Read more
Endocrine Stacking: The Emerging Logic Behind Sermorelin, Pregnenolone, and Enclomiphene
The most interesting developments in endocrine medicine rarely arrive as new drugs. They arrive as new combinations. In small metabolic...
Read more
Layered Physiology: The Treatment Puzzle of Peptides and Hormone Protocols
A patient rarely arrives with a blank endocrine slate. More often the physician inherits a physiological landscape already modified by...
Read more
When the Body Interprets the Drug
A peptide does not simply act on the body. The body interprets it. This interpretive dimension of biosignaling rarely appears...
Read more
The Architecture of Release: Why Growth Hormone Peptides Are Not Interchangeable
Growth hormone itself is a blunt instrument. The peptides that stimulate it are not. For decades, endocrine therapy relied on...
Read more
Steroid Precursors and Systems Medicine
The modern healthcare system excels at identifying discrete failures. It struggles with systems that degrade slowly across multiple regulatory layers....
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more